Baudax Bio (BXRX) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Baudax Bio Reports Second Quarter 2021 Financial Results and Highlights
August 5, 2021 7:00 AM EDTTotal Number of ANJESO® Vials Sold to End-Users in the Second Quarter 2021 Match Total Vials Sold for the Full Year 2020
ANJESO® Demand Showing Strong Growth Based on Several Key Quarter-Over-Quarter Metrics (Second Quarter of 2021 Compared to First Quarter of 2021);
 Total Number of Vials Sold to All Customers Up 30%  Vials Sold to Hospitals and ASCs Combined Up 46%  Vials Sold to Existing Hospitals Up 55%  Vials Sold to New Ambulatory Surgery Centers Up 150%
Formulary Wins: 82% Success Rate at P&T... More
